Posted on: January 10, 2022
Sotrovimab is a monoclonal antibody that neutralizes the spike protein of the SARS-COV-2 virus, preventing entry into human cells and replication. Sotrovimab is active against variants of concern including Omicron.
Clinical Practice Guide for the Use of Sotrovimab in Patients with COVID-19